NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, formulation, and manufacture of poorly soluble molecules, today announced that it has entered into a collaboration with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines. KC Pharmaceuticals will leverage Ascendia’s formulation development and analytical testing capabilities to develop these new products. KC Pharmaceuticals will leverage its manufacturing and distribution expertise to commercialize the products.
About Ascendia Pharmaceuticals LLC
Ascendia is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. Ascendia specializes in improving the bioavailability of poorly water soluble drugs using its nano-particle and nano-emulsion based technologies. Ascendia formulates products for injection (IV, SC or IM); transdermal, ophthalmic or nasal delivery; and both immediate-release and controlled-release products for oral administration. The company has three technology platforms - EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles. For more information, please visit Ascendia’s website at www.ascendiapharma.com.
About KC Pharmaceuticals, Inc.
KC Pharmaceuticals is a leading and trusted supplier in the private store brand category offering a full range of ophthalmic eye drop formulas and contact lens solutions. KC Pharmaceuticals, located in Pomona, California for the past 30 years, also offers industry leading contract ophthalmic product manufacturing services.